Multimorbid AF patients were more likely to receive angiotensin-converting enzyme inhibitors (ACEi), AT1 receptor blockers, loop diuretics and statins, and polypharmacy was more common among these patients than in patients without multimorbidity (Table 2). The gene discussed is ACE; the disease is atrial fibrillation.